Literature DB >> 9841770

Long-term survival after resection of proximal bile duct carcinoma (Klatskin tumors).

M F Gerhards1, T M van Gulik, A Bosma, H ten Hoopen-Neumann, P C Verbeek, D Gonzalez Gonzalez, L T de Wit, D J Gouma.   

Abstract

This retrospective study in 79 surgically treated patients with a proximal bile duct carcinoma revealed 12 patients with a median age of 59.5 years (range 21-73 years) who survived more than 5 years. These 12 patients were analyzed to identify specific patient characteristics for long-term survival. Fifteen patients died from postoperative complications and were excluded from this survival analysis. In relation with preoperative Bismuth classification, there were 3 (20%) long-term survivors of 15 patients with type I tumors and 9 (35%) long-term survivors of 26 patients with type II tumors. In the group of type III and IV tumors, there were no long-term survivors. Concerning the type of resection, 9 of 51 (18%) patients had long-term survival after local resection and 3 of 13 (23%) patients after local resection combined with hemihepatectomy. Complete tumor-free surgical specimen margins were found in only 4 of 64 cases (6%), among which only one patient survived more than 5 years. Negative proximal bile duct margins, absence of multifocality, and diploid tumors showed a significant correlation with long-term survival. There was no significant correlation between long-term survival and postoperative radiotherapy. Of the 12 long-term survivors, 5 died after 5 years: 2 had developed metastases and 1 a local recurrence; the other 2 died of a metastasis of an ovarian adenocarcinoma and cachexia, respectively. The remaining seven patients were still alive at the completion of this study. The mean survival of the 64 patients analyzed in this study (in which hospital mortality was excluded) was 33.7 months, with a median survival of 18.8 months. In conclusion, the preoperative Bismuth classification of the tumor, absence of multifocality, diploid-type tumors, and negative proximal bile duct margins at histopathologic examination were the only significant prognostic factors for long-term survival.

Entities:  

Mesh:

Year:  1999        PMID: 9841770     DOI: 10.1007/s002689900571

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  12 in total

1.  Effectiveness of radiation therapy after surgery for hilar cholangiocarcinoma.

Authors:  Noriaki Sagawa; Satoshi Kondo; Toshiaki Morikawa; Shunichi Okushiba; Hiroyuki Katoh
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

2.  Extended resections for hilar cholangiocarcinoma.

Authors:  P Neuhaus; S Jonas; W O Bechstein; R Lohmann; C Radke; N Kling; C Wex; H Lobeck; R Hintze
Journal:  Ann Surg       Date:  1999-12       Impact factor: 12.969

3.  Hepatic Artery Resection for Bismuth Type III and IV Hilar Cholangiocarcinoma: Is Reconstruction Always Required?

Authors:  Hai-Jie Hu; Yan-Wen Jin; Rong-Xing Zhou; Anuj Shrestha; Wen-Jie Ma; Qin Yang; Jun-Ke Wang; Fei Liu; Nan-Sheng Cheng; Fu-Yu Li
Journal:  J Gastrointest Surg       Date:  2018-03-06       Impact factor: 3.452

4.  Surgical resection for hilar cholangiocarcinoma: experience improves resectability.

Authors:  Robert M Cannon; Guy Brock; Joseph F Buell
Journal:  HPB (Oxford)       Date:  2011-12-12       Impact factor: 3.647

5.  Reduced EBP50 expression levels are correlated with unfavorable clinicopathological features of extrahepatic bile duct carcinoma and promote the proliferation and migration of QBC939 cells.

Authors:  Duiping Feng; Ying Xiong; Zhiqiang Peng; Qiang Ma; Tao Tao; Hua Liu; Jianfang Liang; Zhigang Wei; Junfang Zheng; Lei Wang; Hui Zhang
Journal:  Oncol Lett       Date:  2017-02-28       Impact factor: 2.967

6.  Radiofrequency ablation as a treatment for hilar cholangiocarcinoma.

Authors:  Wei-Jun Fan; Pei-Hong Wu; Liang Zhang; Jin-Hua Huang; Fu-Jun Zhang; Yang-Kui Gu; Ming Zhao; Xiang-Long Huang; Chang-Yu Guo
Journal:  World J Gastroenterol       Date:  2008-07-28       Impact factor: 5.742

7.  The role of liver transplantation in the treatment of hilar cholangiocarcinoma.

Authors:  Hauke Lang; Georgios C Sotiropoulos; Gernot M Kaiser; Ernesto P Molmenti; Massimo Malagó; Christoph E Broelsch
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

8.  The importance of complete excision of the caudate lobe in resection of hilar cholangiocarcinoma.

Authors:  Sander Dinant; Michael F Gerhards; Olivier R C Busch; Hugo Obertop; Dirk J Gouma; Thomas M Van Gulik
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

9.  Prognostic factors and long-term outcomes of hilar cholangiocarcinoma: A single-institution experience in China.

Authors:  Hai-Jie Hu; Hui Mao; Anuj Shrestha; Yong-Qiong Tan; Wen-Jie Ma; Qin Yang; Jun-Ke Wang; Nan-Sheng Cheng; Fu-Yu Li
Journal:  World J Gastroenterol       Date:  2016-02-28       Impact factor: 5.742

10.  Impact of radiotherapy in the management of locally advanced extrahepatic cholangiocarcinoma.

Authors:  Laurence Moureau-Zabotto; Olivier Turrini; Michel Resbeut; Jean-Luc Raoul; Marc Giovannini; Flora Poizat; Gilles Piana; Jean-Robert Delpero; Francois Bertucci
Journal:  BMC Cancer       Date:  2013-12-03       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.